UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dose/exposure–response modeling in dose titration trials: Overcoming the titration paradox

CPT: pharmacometrics and systems pharmacology, 2022-12, Vol.11 (12), p.1592-1603

2022

Volltextzugriff (PDF)

Response to “mixed‐effects models and the drug titration paradox”

CPT: pharmacometrics and systems pharmacology, 2023-04, Vol.12 (4), p.430-431

2023

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials

Clinical pharmacokinetics, 2019-01, Vol.58 (1), p.63-75

2019

Volltextzugriff (PDF)

Impact of dose‐escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model‐based approach

Diabetes, obesity & metabolism, 2020-06, Vol.22 (6), p.969-977

2020

Volltextzugriff (PDF)

Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan

The journal of clinical endocrinology and metabolism, 2021-02, Vol.106 (2), p.567-576

2021

Volltextzugriff (PDF)

Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin® in Children and Adults

Clinical pharmacokinetics, 2021-09, Vol.60 (9), p.1217-1226

2021

Volltextzugriff (PDF)

Identification and preclinical development of an anti-proteolytic uPA antibody for rheumatoid arthritis

Journal of molecular medicine (Berlin, Germany), 2020-04, Vol.98 (4), p.585-593

2020

Volltextzugriff (PDF)

Prediction of human pharmacokinetics of activated recombinant factor VII and B-domain truncated factor VIII from animal population pharmacokinetic models of haemophilia

European journal of pharmaceutical sciences, 2018-03, Vol.115, p.196-203

2018

Volltextzugriff (PDF)

The kidneys play a central role in the clearance of rhGH in rats

European journal of pharmaceutical sciences, 2016-04, Vol.86, p.29-33

2016

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects

Diabetes care, 2002-08, Vol.25 (8), p.1398-1404

2002

Volltextzugriff (PDF)

Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes

Diabetes (New York, N.Y.), 2002-02, Vol.51 (2), p.424-429

2002

Volltextzugriff (PDF)

Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration

European journal of pharmaceutical sciences, 2014-06, Vol.56, p.65-69

2014

Volltextzugriff (PDF)

Nephrectomized and Hepatectomized Animal Models as Tools in Preclinical Pharmacokinetics

Basic & clinical pharmacology & toxicology, 2013-08, Vol.113 (2), p.75-86

2013

Volltextzugriff (PDF)

Blockade of NKG2D ameliorates disease in mice with collagen‐induced arthritis: A potential pathogenic role in chronic inflammatory arthritis

Arthritis & rheumatology (Hoboken, N.J.), 2011-09, Vol.63 (9), p.2617-2629

2011

Volltextzugriff (PDF)

The kidneys play an important role in the clearance of rFVIIa in rats

Thrombosis research, 2014-06, Vol.133 (6), p.1124-1129

2014

Volltextzugriff (PDF)

Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz–type protease inhibitor 2 domain of Tissue Factor Pathway Inhibitor

Thrombosis research, 2014-03, Vol.133 (3), p.464-471

2014

Volltextzugriff (PDF)

Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative

European journal of pharmaceutical sciences, 2003-06, Vol.19 (2), p.141-150

2003

Volltextzugriff (PDF)

The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects

Regulatory peptides, 2006-12, Vol.137 (3), p.168-172

2006

Volltextzugriff (PDF)

Intravascular inhibition of factor VIIa and the analogue NN1731 by antithrombin

British journal of haematology, 2011-01, Vol.152 (1), p.99-107

2011

Volltextzugriff (PDF)

Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma

Thrombosis and haemostasis, 2010-07, Vol.104 (1), p.157-164

2010

Volltextzugriff (PDF)

Clearance of rFVIIa and NN1731 after intravenous administration to Beagle dogs

European journal of pharmaceutical sciences, 2011-04, Vol.42 (5), p.578-583

2011

Volltextzugriff (PDF)

A Population Pharmacokinetic Model for Concizumab Based on Phase 1 and Phase 2 Trial Data

Blood, 2020-11, Vol.136 (Supplement 1), p.4-4

2020

Volltextzugriff (PDF)

Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic–pituitary–gonadal axis following treatment with GnRH analogues

British journal of clinical pharmacology, 2007-06, Vol.63 (6), p.648-664

2007

Volltextzugriff (PDF)

Stochastic differential equations in NONMEM: implementation, application, and comparison with ordinary differential equations

Pharmaceutical research, 2005-08, Vol.22 (8), p.1247-1258

2005

Volltextzugriff (PDF)

1 – 25 von 67

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(67)

Sprache

Englisch
(67)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dose/exposure–response modeling in dose titration trials: Overcoming the titration paradox

Response to “mixed‐effects models and the drug titration paradox”

Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials

Impact of dose‐escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model‐based approach

Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan

Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin® in Children and Adults

Identification and preclinical development of an anti-proteolytic uPA antibody for rheumatoid arthritis

Prediction of human pharmacokinetics of activated recombinant factor VII and B-domain truncated factor VIII from animal population pharmacokinetic models of haemophilia

The kidneys play a central role in the clearance of rhGH in rats

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects

Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes

Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration

Nephrectomized and Hepatectomized Animal Models as Tools in Preclinical Pharmacokinetics

Blockade of NKG2D ameliorates disease in mice with collagen‐induced arthritis: A potential pathogenic role in chronic inflammatory arthritis

The kidneys play an important role in the clearance of rFVIIa in rats

Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz–type protease inhibitor 2 domain of Tissue Factor Pathway Inhibitor

Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide

Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative

The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects

Intravascular inhibition of factor VIIa and the analogue NN1731 by antithrombin

Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma

Clearance of rFVIIa and NN1731 after intravenous administration to Beagle dogs

A Population Pharmacokinetic Model for Concizumab Based on Phase 1 and Phase 2 Trial Data

Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic–pituitary–gonadal axis following treatment with GnRH analogues

Stochastic differential equations in NONMEM: implementation, application, and comparison with ordinary differential equations

Suchergebnisse filtern